IDCRC Investigator Profile: Jennifer Nayak, MD

University of Rochester Vaccine and Treatment Evaluation Unit (VTEU)

Jennifer Nayak, MD, is an associate professor in the Department of Pediatrics, Infectious Diseases, and the Department of Microbiology and Immunology at the University of Rochester. Her current research interests involve:

Understanding how a child's early exposure to influenza shapes immunity and poises the immune system to respond to subsequent influenza challenge
Utilizing CD4 T cell-mediated immunity to improve vaccines directed against pandemic strains of influenza
Understanding how pre-existing CD4 T cells directed against influenza influence the ability of B cells to respond to influenza vaccination

Dr. Nayak serves as the site principal investigator for the IDCRC PROMISE study. Read more about this study here.

How long have you worked with a VTEU?

I am a pediatric infectious diseases subspecialist and first started working with the University of Rochester VTEU as part of the Moderna mRNA-1273-P204 KidCove study in 2021.

Can you share more about a current IDCRC study you're working on?

I am currently serving as the site principal investigator for the University of Rochester on the PROMISE trial. This study is evaluating the effects of maternal vaccination and infant monoclonal antibody administration on RSV antibody levels in mothers and infants, providing essential insights into how these interventions function independently and in combination. Read about IDCRC Studies

Briefly describe the IDCRC-supported trials you’ve supported.

To date, I have worked on the KidCove trial, the adolescent arm of the mPox trial, and the PROMISE trial.

Of these trials, what has been the most impactful or a highlight of the work?

In my opinion, the KidCove trial has been one of the most impactful IDCRC studies. It helped to extend COVID-19 vaccination to the pediatric population, enabling its rigorous evaluation in children and helping to support their safe return to schools and activities—restoring a sense of normalcy for families nationwide.

What is a strength or example of the importance of the IDCRC during the pandemic and beyond?

The strength of the IDCRC lies in its flexibility and inclusiveness, which enable the network to rapidly respond to emerging infectious threats through research spanning the entire human lifespan. This adaptable infrastructure is vital for addressing infectious diseases that are newly emerging or increasing in prevalence.

What do you like to do outside of the VTEU?

I love to spend time with my family, especially my husband and three daughters. I am always up for any adventure that gets us outside and exploring the world!